Funding for this research was provided by:
National Natural Science Foundation of China (81102268,81471615)
13th Five-Year National Science and Technology Major Project for New Drugs of the Ministry of Science and Technology of China (2019ZX09734001-002-004)
Chinese National Key Technology R&D Program of Ministry of Science and Technology (2017YFC0907604)
Medical and health science and technology innovation project of Chinese Academy of Medical Sciences (2019-I2M-2-008)
Received: 2 August 2020
Accepted: 28 December 2020
First Online: 11 January 2021
Ethics approval and consent to participate
: This study was approved by the medical ethics committee of Peking Union Medical College Hospital (PUMCH) and the ethics committee of the European League Against Rheumatism Scleroderma Trial and Research Group (EUSTAR). The procedures for care and use of animals were approved by the animal experimentation ethics committee of PUMCH.
: Not applicable.
: The authors declare no conflicts of interest to any part of this manuscript.